Abstract: Hepatocellular carcinoma is the most common form of liver cancer. It is the seventh-most-common type of cancer worldwide and the third-most-common cause of cancer death worldwide. Most risk factors associated with the development of hepatocellular carcinoma lead initially to liver cirrhosis, which occurs in the majority of hepatocellular carcinoma patients. Treatment of hepatocellular carcinoma incorporates a variety of approaches, and resectability is the key determinant of treatment. However, therapeutic options for hepatocellular carcinoma are limited; only one targeted agent is approved Nexavar (Bayer HealthCare/Onyx Pharmaceuticals’ sorafenib). It is approved for the primary treatment of advanced hepatocellular carcinoma. As a result, the hepatocellular carcinoma therapy market is largely untapped and thus presents a lucrative opportunity for drug development. The hepatocellular carcinoma late-stage pipeline is buoyant; therapies from a range of drug classes are expected to diversify treatment options over the forecast period. Questions answered: How large is the drug-treatable hepatocellular carcinoma population, and how will drug-treatment rates change over time? What is the current state of treatment in hepatocellular carcinoma? Which are the most important treatments and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled? What pipeline products are most promising, and what sales/uptake could they secure in hepatocellular carcinoma? What therapies of note are progressing in earlier phases? What are the drivers and constraints in the hepatocellular carcinoma market, and how will the market evolve over the forecast period? Scope: Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan. Primary research: Ten country-specific interviews with thought leaders. Epidemiology: Diagnosed incident cases of hepatocellular carcinoma: early-stage hepatocellular carcinoma, intermediate-stage hepatocellular carcinoma, and advanced-stage hepatocellular carcinoma. Population segments in market forecast: Intermediate-stage hepatocellular carcinoma, advanced first-line hepatocellular carcinoma, and advanced second-line hepatocellular carcinoma. Emerging therapies: Phase III: 11 drugs; Phase II: 14 drugs; coverage of select preclinical and Phase I products.